Skip to main content

AstraZeneca PLC

AZN
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0000901832

In the last 90 days, AstraZeneca PLC insiders filed 1 open-market purchase and 0 sales; 1,511 institutions reported holding it in 13F filings for Q2 2026, worth $151.3B in total; no superinvestor holds it.

Superinvestors holding AZN, Q2 2026

See all superinvestors

No superinvestor reported holding AZN in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of AZN each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q1 2026

    0 superinvestors holding at quarter end

    Sold out
    Harris Associates (Oakmark)
  2. Q4 2025

    1 superinvestor holding at quarter end

    New
    Harris Associates (Oakmark)
  3. Q2 2025

    0 superinvestors holding at quarter end

    Sold out
    Soros Fund Management
  4. Q1 2025

    1 superinvestor holding at quarter end

    Reduced
    Soros Fund Management (−13.1%)
  5. Q4 2024

    1 superinvestor holding at quarter end

    Added
    Soros Fund Management (+19.0%)
  6. Q3 2024

    1 superinvestor holding at quarter end

    Added
    Soros Fund Management (+8.2%)
    Sold out
    HHLR Advisors (Hillhouse)
  7. Q2 2024

    2 superinvestors holding at quarter end

    New
    HHLR Advisors (Hillhouse)
    Added
    Soros Fund Management (+512.9%)
  8. Q1 2024

    1 superinvestor holding at quarter end

    New
    Soros Fund Management
  9. Q4 2021

    0 superinvestors holding at quarter end

    Sold out
    Maverick Capital
  10. Q3 2021

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−7.3%)
  11. Q2 2021

    1 superinvestor holding at quarter end

    Reduced
    Maverick Capital (−55.6%)